Bellicum Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bellicum Pharmaceuticals, Inc. (BLCM) develops novel cellular immunotherapies for hematological cancers and solid tumors primarily in the United States and internationally; its core products include BPX-601, an autologous GoCAR-T candidate in Phase 1/2 trials targeting prostate stem cell antigen-expressing solid tumors, BPX-603, a dual-switch GoCAR-T candidate in Phase 1/2 trials for human epidermal growth factor receptor 2-expressing solid tumors, and earlier candidates such as Rivo-cel (rivogenlecleucel) for acute lymphoblastic leukemia in Phase 3, Anti-CD19 CAR-T therapy in Phase 2, Rimiducid for primary immunodeficiencies in Phase 1/2, iC9-CAR.CSPG4 T cells for head and neck cancers in Phase 1/2, and TROP2-CAR-NK cells for advanced solid neoplasms in Phase 1; the company leverages proprietary technologies including CaspaCIDe self-destruct switches and DeCIDe activation switches to enhance safety and efficacy in CAR-T, NK cell, and stem cell therapies targeting oncology, hemic/lymphatic diseases, immune disorders, and metabolic conditions. Founded in 2004 and headquartered in Houston, Texas, Bellicum maintains collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys Inc., BioVec Pharma Inc., ARIAD Pharmaceuticals Inc., and Baylor College of Medicine to advance its pipeline across patient-derived autologous and allogeneic cell products. In a significant recent development, MD Anderson Cancer Center acquired key assets from Bellicum in 2024 related to the CaspaCIDe and GoCAR platforms, enabling continued innovation in controllable cell therapies while Bellicum focuses on remaining clinical programs amid a streamlined biotech landscape.
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
BLCM Stock: Over 12% Increase Pre-Market Explanation
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update